Kornimate/medical-research-clean huggingface dataset:
study of the effects of the consumption of different products cocoa derivatives at the risk of crystallization of uric acid in urine of volunteers.

Conditions: Lithiasis, Urinary

Summary: the present study aims to assess the effectiveness of theobromine, -product present in high proportion in the cacao-, to prevent the development of uric acid kidney stones.

renal lithiasis is a pathology that affects a high percentage of the population, and although it has been known for a long time, advances carried out in the treatment are limited to the surgical aspects, while the causes responsible for the formation of kidney calculus are not corrected, which leads to a high recurrence. the "healing" of renal lithiasis inevitably goes through the elimination of the alterations related to the genesis of kidney calculus. it the case of uric acid lithiasis the most important are having urinary ph less than 5.5 and an elevated uricosuria, which can be corrected relatively easy by undergoing changes in dietary habits, and with pharmacological treatment with citrate -which produces and increase in ph- or with inhibitors of the xantino-oxidase as allopurinol. however, among the prophylactic treatments available for ural acid lithiasis, so far it does not exist one for urinary acid crystallization inhibition. recently, the effects of theobromine as an inhibitor of the crystallization of uric acid have been described, but only in vitro. the present study aims to assess the effectiveness of theobromine, -product present in high proportion in the cacao-, to prevent the development of uric acid kidney stones. the study is a unicentric, low intervention, non-randomized, prospective study to assess the effects of the consumption of different cocoa derivate products, in the risk of crystallization of uric acid in the urine. participants in the study are healthy volunteers and will it will be carried out with 20 individuals who will be recruited in the research laboratory in renal lithiasis of the baleares isles university. patients will take a urine test previously to undergo 4 dietary interventions, with their subsequent urine measurements. patients will choose one diet to follow for 1 day, and will be provided with the corresponding cocoa derivate for the diet (soluble cocoa, black chocolate, chocolate with milk). the day after the diet they will take a fast-picking of urine accumulated during the night of which they followed the controlled diet (12 h nocturne sample), then follow a 6 day washout period, and select another diet to follow and repeat until they have gone through the 4 diets and measurements.

Eligibility criteria:
inclusion criteria: * compliance in participating and collaborating in the study exclusion criteria: * cocoa / chocolate allergy or theobromine * pregnancy, nursing period (women) * pharmacological treatment * chronic diseases (diabetes, kidney failure, heart failure, hyperuricemia, ...)

Keywords: lithiasis uric acid crystallization
observational study of nevirapine extended release in human immunodeficiency virus (hiv) patients in daily clinical practice

Conditions: HIV Infections

Summary: this post marketing surveillance study will be performed as an open-label, prospective, non-interventional, uncontrolled study in human immunodeficit virus-1 (hiv-1) infected patients. data will only be documented in patients for whom a pharmacotherapy with nevirapine extended release is initiated. both anti-retroviral therapy (art) naïve patients and pre-treated patients switching from nevirapine immediate release or other anti-retroviral therapy (art) will be included in the study. the decision to initiate treatment with nevirapine extended release is independent of this study and is based entirely on individual patient need and the judgement of the treating physician. the aim of the study is to assess the safety and efficacy and treatment adherence of nevirapine extended release in hiv-1 infected patients in routine clinical practice. it is planned to document five visits for each patient over a twenty four week observational period.

study design: non-interventional uncontrolled observational study

Eligibility criteria:
inclusion criteria: 1. hiv-1 infected male and female 18 years and above; 2. anti-retroviral therapy (art) naive and pre-treated patients switching from a nevirapine immediate release or other art. exclusion criteria: consistent with the current viramune prolonged release spc.
a phase 4 two dose level study of naglazyme(tm) (galsulfase) in infants with mps vi

Conditions: Mucopolysaccharidosis VI; Maroteaux-Lamy Syndrome

Summary: the purpose of the study is to evaluate the safety and efficacy of two dose levels of naglazyme in infants under the age of one year who have mps vi by monitoring physical appearance, x-ray of the skeletal system and growth.

the primary objective of the study was to evaluate the efficacy of two dose levels of naglazyme in preventing the progression of skeletal dysplasia in infants under the age of one year who have mps vi by monitoring physical appearance, x-ray of the skeletal system and growth. the secondary objective of the study was to evaluate the efficacy of the two dose levels of naglazyme in preventing several measures of disease progression in infants under the age of one year who have mps vi by monitoring urinary gags, gross and fine motor function, cardiac function, vision, hearing, and use of health resources. the safety objective of the study was to evaluate the safety of two dose levels of naglazyme in infants under the age of one year who have mps vi.

Eligibility criteria:
inclusion criteria: * signed informed consent by a parent or legal guardian * parent or legal guardian willing and able to comply with all study procedures * equal to or greater than 36 weeks estimated gestational age by physical exam at birth * has a diagnosis of mps vi based on a documented prenatal diagnosis or fibroblast or leukocyte n-acetylgalactosamine 4-sulfatase (asb) enzyme activity level of less than 10% of the lower limit of the normal range of the measuring laboratory * is less than one year of age * has no evidence of skeletal dysplasia based on physical exam exclusion criteria: * parent of legal guardian perceived to be unreliable or unavailable for study participation * use of any investigational drug within 30 days prior to screening, or requirement for any investigational agent prior to completion of all scheduled study assessments * has concurrent disease or condition that would interfere with study participation or safety (i.e., has previously undergone hematopoietic stem cell transplantation such as bone marrow or cord blood transplantation, or major organ transplantation) * any condition that, in the view of the principle investigator, renders the subject at high risk from treatment compliance and/or completing the study * has known hypersensitivity to naglazyme * has previously received naglazyme
a study of bms-986416 with and without nivolumab in select solid tumors

Conditions: Advanced Solid Tumors

Summary: the purpose of this study is to evaluate the safety, tolerability, drug effects, drug levels and preliminary antitumor activity of bms-986416 when administered alone and in combination with nivolumab in participants with select advanced solid tumors.


Eligibility criteria:
inclusion criteria: * participants with histologically or cytologically confirmed locally advanced unresectable, metastatic, or recurrent select solid tumor * eligible tumor types non-small cell lung cancer (nsclc), urothelial carcinoma (uc), squamous cell carcinoma of the head and neck (scchn), hepatocellular carcinoma (hcc), microsatellite-stable colorectal carcinoma (mss crc), or pancreatic ductal adenocarcinoma (pdac) * resistant/refractory to or intolerant of existing standard therapies known to provide clinical benefit * measurable disease per response evaluation criteria in solid tumors version 1.1 (recist v 1.1) * disease amenable to serial biopsy exclusion criteria: * uncontrolled or significant cardiovascular disease * known connective tissue disease such as marfan, ehlers-danlos, or loeys-dietz syndrome * medical requirement for chronic anticoagulant or antiplatelet agents (except low-dose aspirin, which is permitted) other protocol-defined inclusion/exclusion criteria apply

Keywords: bms-986416 nivolumab opdivo non-small cell lung cancer (nsclc) urothelial carcinoma (uc) squamous cell carcinoma of the head and neck (scchn) hepatocellular carcinoma (hcc) microsatellite-stable colorectal carcinoma (mss crc) pancreatic ductal adenocarcinoma (pdac)
intraoperative subanesthetic ketamine versus dexmedetomidine infusion for prevention of post-traumatic stress disorder after traumatic brain surgeries

Conditions: Subanesthetic Ketamine Dexmedetomidin

Summary: prevention of post-traumatic stress disorder after traumatic brain surgeries by using either subanesthetic ketamine or dexmedetomidine infusion.

after being informed about the study and potential risks. all patients giving written consent will be randomized by double blind manner into two equal groups (k group and d group). using computer generated randomization table; each group consists of 26 patients: k group (n=26): patient will receive with 0.5 mg/kg/h ketamine infusion. d group (n=26): patient will receive 0.1 ug/kg/h dexmedetomidine infusion.

Eligibility criteria:
inclusion criteria: aged 18-60 years old.body mass index of less than or equal 35.american society of i and ii.duration of surgery not more than 3 hours. exclusion criteria: known hypersensitivity to dexmedetomidine or ketamine. hemorrhagic shock decompensation.history of alcohol or drug abuse.history of neurologic or psychiatric diseases advanced renal ,liver or cardiovascular disorders.

Keywords: ketamine, dexmedetomidine ,post-traumatic stress disorder , traumatic brain surgeries
effects of octa-guided pdt in acute csc

Conditions: Central Serous Chorioretinopathy; Tomography, Optical Coherence

Summary: octa-guided pdt is as safe and effective as icga-guided pdt in the treatment of acute central serous chorioretinopathy. or octa-guided pdt is more effective than icga-guided pdt in the treatment of acute central serous chorioretinopathy, safe as well.


Eligibility criteria:
inclusion criteria: * idiopathic detachment of the neurosensory retina with a focal leak at the level of the rpe with fa * presence of srf and/or serous pigment epithelial detachment on oct * presence of abnormal dilated choroidal vasculature in icga exclusion criteria: * patients with other ocular conditions commonly associated with srf, such as choroidal neovascularization, polypoidal choroidal vasculopathy (pcv), diabetic retinopathy, retinal vascular occlusion, coat's disease * any disease that may affect the quality of imaging (quality of octa images \< 6), such as cataract, high myopia or nystagmus * history of ocular surgeries including retinal laser * pregnancy * any uncontrolled systemic disease * any condition rendering patients intolerable to image acquisition

Keywords: optical coherence tomography angiography central serous chorioretinopathy photodynamic therapy
a spanish medical record review of clinical characteristics and outcomes in non-small cell lung cancer participants with egfr exon 20 insertion

Conditions: Non-small Cell Lung Cancer (NSCLC)

Summary: the main aim is to evaluate sociodemographic and clinical characteristics of advanced non-small cell lung cancer (nsclc) in adults participants with epidermal growth factor receptor (egfr) exon 20 insertions mutations during the 5 years before data extraction date (from 1-jan-2017 to 1-jan-2022). participants will not receive any drug. this study will only collect the data from the medical records via chart review.

this is an observational, non-interventional, retrospective study in participants with nsclc with egfr exon 20 insertions mutations. this study will assess the sociodemographic and clinical characteristics of advanced nsclc participants. the study will enroll approximately 60 participants. participants who were evaluated and treated at the participating sites between 01 january 2017 and 30 september 2021 will be included. the data will be collected from the medical record of participants via medical chart review. all the participants will be assigned to a single observational cohort: • participants with advanced nsclc with egfr exon 20 insertions mutations this multi-center trial will be conducted in spain. the overall duration of the study will be approximately 27 months.

Eligibility criteria:
inclusion criteria: 1. participants with a pathologically and/or cytologically confirmed diagnosis of advanced stage nsclc (international classification of disease, 10th revision \[icd-10\] c34.x), either primary, advanced or after relapse of initial non-metastatic disease, evaluated and treated during the last five years prior data extraction date from 1-jan-2017 to 1-jan-2022. 2. participants with detection of an egfr exon 20 insertion mutation, at any point. 3. has documentation available for at least 2 visits since the initiation of the last treatment within the last five years (1-january-2017 to 1-january-2022). exclusion criteria: 1. participants do not meet any of the inclusion criteria.

Keywords: drug therapy
cervical changes by 4h of hyper-buoyancy flotation and followed by 15 mins 1g re-loading

Conditions: Intervertebral Disc Herniation; Stiffness; Spine

Summary: study with the aim to see the effect on a space ground anaologue, hyperbuoyancy floatation (hbf) on cervical column.

the aim of the study is to determine the effect of 4h hbf and subsequent passive 1g axial loading upon stature, cervical ivd height) cervical muscle (longus collis and semispinalis cervicis) thickness and csa assessed with ultrasound, cervical vertebral compliance, their relationships to induced stature increments and neck pain.

Eligibility criteria:
inclusion criteria: * physical requirements (1.57-1.90m, 50-95kg) exclusion criteria: * current back/neck pain, musculoskeletal disorder, cardiovascular disease, spine surgery and being, or suspected to be pregnant
pathogenesis of youth onset type 2 diabetes and prediabetes

Conditions: IGT - Impaired Glucose Tolerance; T2D

Summary: type 2 diabetes (t2d) in obese youth is often preceded by a prediabetic state called: impaired glucose tolerance (igt), which is associated with a pre-existing defect in insulin secretion. this study intends to determine if genetic factors are associated with defects in insulin secretion, the incretin system and hepatic insulin resistance in obese adolescents. the long-term goal of this study is to generate information on both the genetics as well as the pathophysiology of type 2 diabetes in youth, which ultimately might guide the investigators towards better preventive and treatment avenues.

the specific aims of this study are: aim 1a. to delineate the effects of tcf7l2 rs7903146 on functional beta-cell capacity in obese adolescents with impaired glucose tolerance (igt) and pre-igt. aim 1b. to determine if the risk genotype in tcf7l2 is associated with worsening in beta cell function longitudinally, thereby affecting changes in glucose tolerance. aim 2. to examine the functional effect of the rs7903146 variant in the tcf7l2 gene on a) incretin effect in obese adolescents with igt and pre-igt. aim 3. to determine the functional effects of tcf7l2 rs7903146 snp on hepatic glucose fluxes in obese adolescents with igt and pre-igt.

Eligibility criteria:
inclusion criteria: * good general health, taking no medication on a chronic basis; * age 12 to 18 yrs, in puberty (girls and boys: tanner stage ii - iv), * bmi (bmi \>85th%) indicating obesity, * girls who are menstruating must have a negative pregnancy test during the study and, when possible, be in the follicular phase during infusion study visits (the follicular phase will be identified according to the last menstrual period record and/or according to the oral contraceptive assumption schedule. the investigators will not perform ovulation testing or hormonal assays); * subject must have normal liver and kidney function, amylase and lipase levels. * pre-igt or igt * tt or cc genotype. exclusion criteria: * baseline creatinine \>1.0 mg; * pregnancy; * presence of endocrinopathies (e.g. cushing syndrome); * cardiac, renal or pulmonary or other chronic illness; * adolescents with psychiatric disorder or with substance abuse history and taking the drugs that affect glucose metabolism, such as any form of steroids, antipsychotics, progesterone preparations, and others.
dose response and receptor selectivity of beta-blocker effects on bone metabolism

Conditions: Osteoporosis, Age-Related

Summary: this study is designed to answer the question as to whether the sympathetic nervous system is an important determinant of bone metabolism in humans.

in postmenopausal women, who have increased sympathetic outflow, to test the hypothesis that treatment with low doses of a non-selective β-blocker (propranolol) will increase serum markers of bone formation and reduce markers of bone resorption (aim 1a); and using increasingly β1-ar (adrenergic receptor) selective blockers (atenolol and nebivolol), to better define the β-adrenergic receptor selectivity (β1 versus β2) in the regulation of bone turnover by sympathetic outflow in humans.

Eligibility criteria:
* inclusion criteria: * at least 5 yrs since their last menses * follicle stimulating hormone (fsh) \> 20 iu/l * exclusion criteria: * abnormality in any of the screening laboratory studies * presence of significant liver or renal disease * malignancy (including myeloma) * malabsorption * diabetes * hypoparathyroidism * hyperparathyroidism * acromegaly * cushing's syndrome * hypopituitarism * severe chronic obstructive pulmonary disease * undergoing treatment with any medications that affect bone turnover, including the following: * adrenocorticosteroids (\> 3 months at any time or \> 10 days within the previous yr) * anticonvulsant therapy (within the previous year) * pharmacological doses of thyroid hormone (causing decline of thyroid stimulating hormone below normal) * calcium supplementation of \> 1200 mg/d (within the preceding 3 months) * bisphosphonates (within the past 3 yrs) * denosumab * estrogen (e) therapy within the past year * treatment with a selective e receptor modulator within the past year * teriparatide within the past yr * anti-hypertensive therapy * clinical history of osteoporotic fracture (vertebral, hip, or distal forearm * recent (within the past 6 months) fracture * serum 25-hydroxyvitamin d levels of \< 20 ng/ml * resting blood pressure \>140/90 mm hg or those with hypotension (systolic blood pressure \<110 mm hg), heart rate \< 60 bpm * history of asthma

Keywords: bone formation
observational study evaluating long-term health outcomes of canadian duodopa-treated patients

Conditions: Parkinson Disease (PD)

Summary: this is an open-label, postmarketing, observational study to document health outcomes, in canadian patients with advanced parkinson's disease and long-term treatment with duodopa (levodopa/carbidopa intestinal gel).


Eligibility criteria:
inclusion criteria: * diagnosed with advanced parkinson's disease * prescribed duodopa by his/her treating physician. exclusion criteria: * patients who were previously treated with duodopa. * presence of other condition that, in the opinion of the treating physician, prohibits the patient from participating in the study or obscures the assessment of the treatment of advanced pd.

Keywords: cadence duodopa parkinson's disease lcig levodopa-carbidopa intestinal gel observational
outcomes of surgical resection of pancreatic cystic neoplasms based on the european expert consensus statement: a prospective observational study.

Conditions: Pancreas Cancer

Summary: introduction: pancreatic cystic neoplasms (pcns) comprise neoplasms with a wide range of benign and malignant varieties. the most common include serous cystic neoplasms (scns), mucinous cystic neoplasms (mcns), intraductal papillary mucinous neoplasms (ipmns), and solid pseudo-papillary neoplasms (sppns). endoscopic ultrasonography (eus), computed tomography (ct) and magnetic resonance (mr) are used to diagnose different pcns types. the cyst fluid aspiration and analysis is performed in difficult differential diagnosis. frequently, amylase and cea levels are measured. the choice of surgery depends on cyst location and size and includes pancreatico-duodenectomy or distal pancreatectomy. objectives: the aim of this study was to evaluate the outcomes after pancreatic surgery when adopted as the management of true exocrine epithelial cystic neoplasms.

introduction: pancreatic cystic neoplasms (pcns) comprise neoplasms with a wide range of benign and malignant varieties. the most common include serous cystic neoplasms (scns), mucinous cystic neoplasms (mcns), intraductal papillary mucinous neoplasms (ipmns), and solid pseudo-papillary neoplasms (sppns). endoscopic ultrasonography (eus), computed tomography (ct) and magnetic resonance (mr) are used to diagnose different pcns types. the cyst fluid aspiration and analysis is performed in difficult differential diagnosis. frequently, amylase and cea levels are measured. the choice of surgery depends on cyst location and size and includes pancreatico-duodenectomy or distal pancreatectomy. objectives: the aim of this study was to evaluate the outcomes after pancreatic surgery when adopted as the management of true exocrine epithelial cystic neoplasms. patients and methods: between june 2014 and january 2018, 63 patients referred to our tertiary referral center with diagnosis of true exocrine cystic neoplasms of the pancreas accepted for surgery were included in the present prospective cohort study. patients were categorized according to preoperative diagnosis into: serous cystic neoplasms (group a: 30 patients), mucinous cystic neoplasms (group b: 13 patients), intra-papillary mucinous neoplasms (group c: 9 patients), whereas the last 5 patients diagnosed as solid pseudo-papillary neoplasms (group d). demographic data, perioperative data and univariate analysis for malignancy, recurrence and pancreatic fistula were collected and analyzed.

Eligibility criteria:
inclusion criteria: * any age * both sex, * expected r0 resection, * tumor of any size, * no previous pancreatic surgery with diagnosis of true exocrine pancreatic cystic neoplasms exclusion criteria: * endocrinal pancreatic tumors, * solid pancreatic tumors, * previous pancreatic surgery, * recurrent pancreatic tumor, * combined operation, * prior history of any malignancy and misdiagnosed cases discovered on postoperative pathological cases as pancreatic pseudo-cyst or endocrine tumors
efficacy of ethnodyne visio in parkinson's disease

Conditions: Parkinson's Disease

Summary: ethnodyne visio is a food supplement composed of an innovative plant-based active ingredient acting alongside vitamin b2. it is proposed in patients with visual problems. based on clinical and experimental data, the investigators propose a pilot open study in order to test the efficacy of "ethnodyne visio" in patients with parkinson 's disease (pd). the hypothesis is that ethnodyne visio may improve motor and non motor signs of pd. 24 patients with pd will be evaluated before and after 3 months of add on treatment by ethnodyne visio.


Eligibility criteria:
inclusion criteria: * patients with parkinson disease (pd) with at least 3 years of evolution * hoehn and yahr score 2 or 3 * with moderate fluctuations (score 1 or 2 for item 3 score iv msd updrs) * with no modification in anti-parkinsonian drugs since at least 1 month * minimental test \>24 exclusion criteria: * known intolerance to ethnodyne visio * woman of childbearing potential or breastfeeding * anticipated anti-parkinsonian treatment modification during the 3 months of the study * antidepressant or anxiolytic drugs modified within one month prior to inclusion visit * other chronic disease * concomitant participation in a another clinical trial * subject under legal guardianship

Keywords: treatment motor signs non motor signs fluctuations open labelled